Innoviva Inc Asset Resilience Ratio
Innoviva Inc asset resilience ratio. Innoviva Inc (INVA) has an Asset Resilience Ratio of 0.51% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Innoviva Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Innoviva Inc (2002–2025)
Asset resilience ratio of Innoviva Inc from 2002 to 2025. This chart shows how Innoviva Inc's Asset Resilience Ratio has changed over time. Read INVA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Innoviva Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Innoviva Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.67 Million | 0.51% |
| Total Liquid Assets | $8.67 Million | 0.51% |
Asset Resilience Insights
- Limited Liquidity: Innoviva Inc maintains only 0.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Innoviva Inc Industry Peers by Asset Resilience Ratio
Compare Innoviva Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Innoviva Inc Asset Resilience Ratio by Year (2002–2025)
Innoviva Inc asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Innoviva Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.96% | $15.73 Million | $1.64 Billion | -7.30pp |
| 2024-12-31 | 8.26% | $107.53 Million | $1.30 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $1.24 Billion | -- |
| 2022-12-31 | 32.73% | $403.01 Million | $1.23 Billion | -19.50pp |
| 2021-12-31 | 52.23% | $483.85 Million | $926.39 Million | +8.38pp |
| 2020-12-31 | 43.84% | $438.26 Million | $999.57 Million | +33.81pp |
| 2019-12-31 | 10.04% | $72.75 Million | $724.83 Million | +0.46pp |
| 2018-12-31 | 9.58% | $52.49 Million | $548.19 Million | -5.60pp |
| 2017-12-31 | 15.17% | $55.74 Million | $367.34 Million | +6.62pp |
| 2016-12-31 | 8.55% | $32.42 Million | $379.00 Million | +1.93pp |
| 2015-12-31 | 6.63% | $28.10 Million | $424.07 Million | -20.92pp |
| 2014-12-31 | 27.55% | $143.70 Million | $521.65 Million | -19.66pp |
| 2013-12-31 | 47.21% | $321.62 Million | $681.25 Million | +5.53pp |
| 2012-12-31 | 41.68% | $153.64 Million | $368.58 Million | -34.11pp |
| 2011-12-31 | 75.79% | $196.14 Million | $258.78 Million | +31.62pp |
| 2010-12-31 | 44.17% | $146.30 Million | $331.20 Million | -15.28pp |
| 2009-12-31 | 59.45% | $107.85 Million | $181.39 Million | +13.58pp |
| 2008-12-31 | 45.87% | $108.33 Million | $236.16 Million | +20.94pp |
| 2007-12-31 | 24.93% | $40.38 Million | $161.98 Million | -24.11pp |
| 2006-12-31 | 49.04% | $128.69 Million | $262.42 Million | -0.84pp |
| 2005-12-31 | 49.88% | $112.14 Million | $224.84 Million | -4.57pp |
| 2004-12-31 | 54.45% | $155.73 Million | $286.02 Million | +11.88pp |
| 2003-12-31 | 42.57% | $53.40 Million | $125.45 Million | +21.94pp |
| 2002-12-31 | 20.63% | $39.75 Million | $192.72 Million | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more